Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Assets Average (2020 - 2025)

Historic Assets Average for Nurix Therapeutics (NRIX) over the last 6 years, with Q4 2025 value amounting to $605.3 million.

  • Nurix Therapeutics' Assets Average rose 233.86% to $605.3 million in Q4 2025 from the same period last year, while for Nov 2025 it was $605.3 million, marking a year-over-year increase of 233.86%. This contributed to the annual value of $678.7 million for FY2025, which is 3244.45% up from last year.
  • As of Q4 2025, Nurix Therapeutics' Assets Average stood at $605.3 million, which was up 233.86% from $557.0 million recorded in Q3 2025.
  • Nurix Therapeutics' 5-year Assets Average high stood at $642.2 million for Q1 2025, and its period low was $329.4 million during Q3 2023.
  • Moreover, its 5-year median value for Assets Average was $447.6 million (2022), whereas its average is $462.8 million.
  • Its Assets Average has fluctuated over the past 5 years, first plummeted by 2423.29% in 2023, then skyrocketed by 9219.51% in 2025.
  • Over the past 5 years, Nurix Therapeutics' Assets Average (Quarter) stood at $484.9 million in 2021, then decreased by 9.67% to $438.0 million in 2022, then fell by 24.23% to $331.9 million in 2023, then surged by 78.21% to $591.5 million in 2024, then grew by 2.34% to $605.3 million in 2025.
  • Its last three reported values are $605.3 million in Q4 2025, $557.0 million for Q3 2025, and $603.3 million during Q2 2025.